Pregnancy

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

INPEFA recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon…

2 years ago

Oldest OB-GYN Clinic in Faulkner County Switches to eClinicalWorks Cloud EHR for an AI-Powered Solution to Streamline Operations

Conway OB-GYN Clinic, P.A. to increase efficiencies and interoperability with eClinicalWorks and healow advanced technologiesWESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the largest ambulatory…

2 years ago

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients…

2 years ago

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company…

2 years ago

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update

                  - Patient enrollment has commenced in landmark pivotal trial for lead product…

2 years ago

Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of…

2 years ago

BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)

Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to help them manage their symptoms…

2 years ago

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

-- Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment ---- Early access…

3 years ago